Addition of Dupilumab for Patients with Aspirin-Exacerbated Respiratory Disease who have Poor Response to Aspirin Therapy After Desensitization.
作者信息
Achanta Pooja M, Swirnoff Joel, Parigian Rachel E, Laidlaw Tanya M, Buchheit Kathleen M
机构信息
Beth Israel Deaconess Medical Center, Department of Medicine, Boston, MA.
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA.
出版信息
J Allergy Clin Immunol Pract. 2025 Sep 7. doi: 10.1016/j.jaip.2025.08.032.
Abstract
摘要
相似文献
1
Addition of Dupilumab for Patients with Aspirin-Exacerbated Respiratory Disease who have Poor Response to Aspirin Therapy After Desensitization.对于阿司匹林脱敏后对阿司匹林治疗反应不佳的阿司匹林诱发的呼吸道疾病患者，添加度普利尤单抗治疗。
J Allergy Clin Immunol Pract. 2025 Sep 7. doi: 10.1016/j.jaip.2025.08.032.
2
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease.用于非甾体抗炎药（NSAID）诱发的呼吸道疾病的口服和鼻内阿司匹林脱敏疗法。
Cochrane Database Syst Rev. 2025 Jan 7;1(1):CD013476. doi: 10.1002/14651858.CD013476.pub2.
3
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.阿司匹林脱敏后口服阿司匹林治疗阿司匹林加重的呼吸道疾病患者的作用：美国过敏、哮喘和免疫学会鼻炎、鼻窦炎和眼过敏委员会的一份工作组报告。
J Allergy Clin Immunol. 2021 Mar;147(3):827-844. doi: 10.1016/j.jaci.2020.10.043. Epub 2020 Dec 9.
4
Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.比较达普单抗和阿司匹林脱敏疗法治疗阿司匹林加重性呼吸道疾病伴鼻息肉的慢性鼻-鼻窦炎的成本效果分析。
Int Forum Allergy Rhinol. 2021 Dec;11(12):1626-1636. doi: 10.1002/alr.22865. Epub 2021 Jul 26.
5
Relationship Between Alcohol Intolerance and Aspirin-Exacerbated Respiratory Disease (AERD): Systematic Review.酒精不耐受与阿司匹林加重性呼吸道疾病（AERD）的关系：系统评价。
Otolaryngol Head Neck Surg. 2023 Jul;169(1):12-20. doi: 10.1002/ohn.248. Epub 2023 Jan 29.
6
Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.阿司匹林脱敏与生物制剂在阿司匹林加重的呼吸道疾病中的疗效、耐受性和患者体验。
Ann Allergy Asthma Immunol. 2022 May;128(5):575-582. doi: 10.1016/j.anai.2022.01.043. Epub 2022 Feb 5.
7
Real-world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps.慢性鼻-鼻窦炎伴鼻息肉患者中度普利尤单抗处方的真实世界预测因素
Int Forum Allergy Rhinol. 2025 Mar;15(3):278-286. doi: 10.1002/alr.23483. Epub 2024 Nov 13.
8
Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease.阿司匹林脱敏和维持治疗在阿司匹林加重性呼吸系统疾病中的主要并发症。
Int Forum Allergy Rhinol. 2021 Feb;11(2):115-119. doi: 10.1002/alr.22643. Epub 2020 Jul 16.
9
Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.度普利尤单抗在真实世界中治疗阿司匹林诱发的呼吸道疾病：对生活质量和医疗保健利用的影响。
Am J Rhinol Allergy. 2025 Mar;39(2):90-97. doi: 10.1177/19458924241298817. Epub 2024 Nov 22.
10
[Progress in application of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease].
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Mar 12;47(3):286-291. doi: 10.3760/cma.j.cn112147-20230803-00043.
本文引用的文献
1
Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.度普利尤单抗在真实世界中治疗阿司匹林诱发的呼吸道疾病：对生活质量和医疗保健利用的影响。
Am J Rhinol Allergy. 2025 Mar;39(2):90-97. doi: 10.1177/19458924241298817. Epub 2024 Nov 22.
2
Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi.生物制剂在 NSAID-ERD 中的疗效：从鼻腔到支气管的联合航空。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2917-2932. doi: 10.1016/j.jaip.2024.09.021. Epub 2024 Sep 27.
3
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.脱敏后使用度普利尤单抗和阿司匹林治疗非甾体抗炎药加重的呼吸道疾病的联合治疗。
Clin Exp Allergy. 2023 Sep;53(9):974-977. doi: 10.1111/cea.14348. Epub 2023 May 29.
4
Updates on immune mechanisms in aspirin-exacerbated respiratory disease.阿司匹林加重性呼吸道疾病的免疫机制研究进展。
J Allergy Clin Immunol. 2023 Feb;151(2):301-309. doi: 10.1016/j.jaci.2022.08.021. Epub 2022 Sep 30.
5
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.度普利尤单抗治疗未得到控制的伴有鼻息肉的重度慢性鼻-鼻窦炎和 NSAID-ERD 临床诊断患者的疗效和安全性：两项随机安慰剂对照 3 期临床试验的结果。
Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1.
6
Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.阿司匹林脱敏治疗阿司匹林加重性呼吸道疾病的获益与危害：系统评价和荟萃分析。
Int Forum Allergy Rhinol. 2019 Dec;9(12):1409-1419. doi: 10.1002/alr.22428. Epub 2019 Sep 13.
7
Aspirin-Exacerbated Respiratory Disease.阿司匹林加重性呼吸道疾病
N Engl J Med. 2018 Sep 13;379(11):1060-1070. doi: 10.1056/NEJMra1712125.
8
Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study.用于慢性鼻-鼻窦炎分类的新型评分系统和算法：JESREC研究
Allergy. 2015 Aug;70(8):995-1003. doi: 10.1111/all.12644. Epub 2015 May 26.
9
Medical and surgical considerations in patients with Samter's triad.阿司匹林三联征患者的医学与外科考量
Am J Rhinol. 2006 Nov-Dec;20(6):573-6. doi: 10.2500/ajr.2006.20.2913.
Zotero 插件